Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

March 21, 2023

Amandeep Godara, MBBS, discusses CAR T-cell therapies currently available for patients with multiple myeloma.

March 21, 2023

Varghese, known for his innovative research in perioperative care and mentorship to physician-scientists, will become SUS President in February 2024.

March 20, 2023

Updated data from key trials in non–small cell lung cancer continue to demonstrate the superiority of immunotherapy and targeted therapy regimens for non–small cell lung cancer treatment, but the optimal use of these agents in the adjuvant vs neoadjuvant settings is still contested.

March 17, 2023

Brian Mitzman, MD, FACS, FCCP, discusses findings from the phase 3 CheckMate 816 trial in patients with resectable non–small cell lung cancer.

March 02, 2023

Amandeep Godara, MBBS, discusses the evolving treatment landscape in both early and late relapsed multiple myeloma, updated clinical trial results with CAR T-cell therapy, and key considerations when navigating treatment selection in this disease space.

February 28, 2023

Amandeep Godara, MBBS, expands on the advantages and limitations of teclistamab monotherapy in patients with late-relapsed myeloma, discusses the best use of bispecific antibodies and CAR T-cell therapy in this population, and highlights ongoing efforts to mitigate the impact of treatment-related toxicities and improve accessibility across the paradigm.

February 28, 2023

Experts in hematologic malignancies conclude their discussion by discussing BTK degraders and other targets in the treatment of mantle cell lymphoma.

February 27, 2023

Huntsman Cancer Institute at the University of Utah congratulates three of their newest endowed chairs.

February 21, 2023

A comprehensive look at the role of bispecific antibodies, including glofitamab, in the treatment of mantle cell lymphoma.

February 21, 2023

Bijal D. Shah, MD, and Matthew J. Matasar, MD, discuss how they approach treating patients with MCL who rapidly progress on BTK inhibitors.

February 16, 2023

Talazoparib plus enzalutamide generated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs placebo plus enzalutamide as first-line treatment for patients with metastatic castration-resistant prostate cancer, irrespective of homologous recombination repair status.

February 14, 2023

Sagar Patel, MD, discusses complications following allogeneic stem cell transplant that can occur in patients with myelofibrosis.

February 14, 2023

A panel of experts in hematologic malignancies analyze clinical studies and real-world data of brexucabtagene autoleucel in mantle cell lymphoma.

February 14, 2023

Alexey V. Danilov, MD, PhD, presents a second patient profile of a 60-year-old patient with MCL, and the panel discusses using CAR T-cell therapy to treat MCL.

February 13, 2023

Findings from the MASTER trial in multiple myeloma could help shape how future treatment decisions are approached for fit, transplant-eligible patients.

February 07, 2023

A comprehensive discussion on ways to approach treating patients with high-risk mantle cell lymphoma.

February 07, 2023

A detailed look at how to select the appropriate BTK inhibitor to treat patients with MCL and the potential role of the non-covalent BTK inhibitor pirtobrutinib in MCL.

January 31, 2023

Experts in hematologic malignancies review the role of BTK inhibitors and other therapies in patients with relapsed/refractory mantle cell lymphoma.

January 31, 2023

A panel of experts in hematologic malignancies discuss the SHINE study, which looked at ibrutinib with bendamustine and rituximab in elderly patients with MCL.

September 22, 2022

Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.